PD-1 inhibitors such as pembrolizumab and nivolumab, were most frequently associated with thyroiditis (41–46%) and hypothyroidism (37–38%); hyperthyroidism was also observed (29–32%). This evidence concerns the gene PDCD1 and thyroiditis.